Target intelligence / Profile preview

Serine peptidase inhibitor, Kunitz type 3 (SPINT3)

Target
SPINT3
Molecular classification
Proteinase inhibitor, Kunitz domain-containing protein, Enzyme modulator
01

Overview

Serine peptidase inhibitor, Kunitz type 3 (SPINT3) is a small protein characterized by the presence of a Kunitz-type domain, approximately 50–60 amino acids in length, stabilized by three disulfide bonds. Kunitz-type domains are canonical proteinase inhibitor motifs, acting primarily by binding the active site of serine proteases to block their catalytic activity. Members of the family play central roles in regulating physiological processes such as blood coagulation, tissue inflammation, and the immune response. In some organisms, they protect against microbial pathogens and facilitate collagen synthesis. SPINT3 and related proteins are notable as therapeutic targets and drug scaffolds, especially for disorders involving proteolytic imbalance such as hereditary angioedema. If further granularity (species, isoform, gene) is needed, additional data sources may clarify exact sequence and functional annotation.

Other names
SPINT3Kunitz-type serine protease inhibitor 3Kunitz domain protein 3
02

Mechanism of action

Competitive inhibition of the active site of target serine proteases (e.g., trypsin, kallikrein, elastase) and Allosteric modulation in some cases

03

Biological functions

Protease inhibitionRegulation of blood coagulationInflammatory response modulationMicrobial defenseCollagen biosynthesisAllergy induction
04

Disease associations

Cardiovascular diseaseInflammationInfectionAllergic and autoimmune disordersOther (diverse roles as family is functionally heterogeneous)
05

Safety considerations

Potential for bleedingImmune/allergic reactionsOff-target effects
06

Interacting drugs

Ecallantide

1 more in the full profile.

07

Biomarkers

Level of inhibitor as a biomarker for coagulation disorders, inflammation, or certain infectionsNo established clinical biomarkers for SPINT3 specifically found in the search results

Beyond the preview

Go deeper on Serine peptidase inhibitor, Kunitz type 3 (SPINT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serine peptidase inhibitor, Kunitz type 3 (SPINT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call